MedTrace Logo

New-diagnosed PCNSL Treated With Methotrexate (MTX) and Orelabrutinib-based Regimen

NCT06115824 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 136

Last updated 2025-09-16

No results posted yet for this study

Summary

This study was a single-centre, retrospective study that retrospectively collected first-line PCNSL patients receiving methotrexate-based chemotherapy ± orelabrutinib at Huashan Hospital of Fudan University. The study was divided into two retrospective cohorts, Cohort A was a cohort of patients receiving methotrexate-based chemotherapy alone, and Cohort B was a cohort of patients receiving methotrexate-based chemotherapy + orelabrutinib.

Conditions

Interventions

DRUG

Orelabrutinib

Combination of orelabrutinib on a methotrexate-based chemotherapy regimen with a starting dose of 150 mg/d

Sponsors & Collaborators

  • Huashan Hospital

    lead OTHER

Principal Investigators

  • Tong Chen · Huashan Hospital

  • Tong Chen · Huashan Hospital

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-10
Primary Completion
2024-01-30
Completion
2024-07-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06115824 on ClinicalTrials.gov